{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:23:52Z","timestamp":1793755432932,"version":"4.6.1"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"26","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003793","name":"Swedish Heart Lung Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003793","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Swedish government"},{"name":"ALFagreement","award":["ALFGBG-965404"],"award-info":[{"award-number":["ALFGBG-965404"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>LDL-C and non-HDL-C do not fully capture coronary heart disease (CHD) risk attributed to all apoB-containing lipoproteins. Use of apolipoprotein B (apoB) as a marker of total atherogenic particle number improves risk prediction, but risk may still be underestimated when triglyceride-rich lipoproteins (TRL\/remnants) and lipoprotein(a) [Lp(a)] are elevated. The aim was to formulate a new metric\u2014risk-weighted apoB (RW-apoB)\u2014designed to capture risk from LDL, TRL\/remnants, and Lp(a) in a single number.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Based on previously published estimates of the relative atherogenicity of LDL, TRL\/remnant, and Lp(a) particles, RW-apoB was developed (using UK Biobank data) as an atherogenicity-weighted apoB-sum calculated as: RW-apoB = 11.65\u00d7TG(mmol\/L) + 0.215\u00d7lipoprotein(a)(nmol\/L) + 0.736\u00d7apoB(mg\/dL).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Assigning RW-apoB to individuals substantially reclassified their risk status. Compared with ranking by measured apoB, 52% of individuals were up- or down-ranked by \u226510 percentiles. About one-third of those in the top RW-apoB quintile\u2014with elevated TRL and Lp(a) and a CHD event rate of 5.4%\u2014were misclassified as lower risk by apoB. Conversely, individuals in the top measured apoB quintile but with low TRL and Lp(a) had a lower event rate (3.9%) and were correctly down-ranked. RW-apoB improved risk prediction, significantly increasing Harrell\u2019s C-index relative to apoB (P &amp;lt; .0001). In statin-treated subjects, RW-apoB was potentially a better index of residual risk. RW-apoB consistently outperformed apoB as a risk predictor in Cox models across the UK Biobank and three other large population cohorts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>RW-apoB represents not only particle number but also accounts for the higher atherogenicity of TRL and Lp(a). It offers clinically meaningful improvements in CHD risk stratification.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehaf1124","type":"journal-article","created":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T12:29:43Z","timestamp":1767529783000},"page":"3415-3425","source":"Crossref","is-referenced-by-count":12,"title":["Risk-weighted apoB: a novel summary metric outperforming traditional lipid biomarkers in predicting coronary heart disease"],"prefix":"10.1093","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-3053-6612","authenticated-orcid":false,"given":"Michaela B","family":"Rehman","sequence":"first","affiliation":[{"name":"Cardiology Department, Ramsay Sant\u00e9, M\u00e9dip\u00f4le Lyon-Villeurbanne , Villeurbanne ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0003-6463","authenticated-orcid":false,"given":"Elias","family":"Bj\u00f6rnson","sequence":"additional","affiliation":[{"name":"Institute of Medicine, University of Gothenburg , Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3667-589X","authenticated-orcid":false,"given":"Martin","family":"Adiels","sequence":"additional","affiliation":[{"name":"Institute of Medicine, University of Gothenburg , Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7119-0273","authenticated-orcid":false,"given":"Jakub","family":"Morze","sequence":"additional","affiliation":[{"name":"Institute of Medicine, University of Gothenburg , Gothenburg ,","place":["Sweden"]},{"name":"SciLifeLab, Department of Life Sciences, Chalmers University of Technology , Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4289-5722","authenticated-orcid":false,"given":"G\u00f6ran","family":"Bergstr\u00f6m","sequence":"additional","affiliation":[{"name":"Institute of Medicine, University of Gothenburg , Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Gummesson","sequence":"additional","affiliation":[{"name":"Institute of Medicine, University of Gothenburg , Gothenburg ,","place":["Sweden"]},{"name":"Department of Clinical Genetics and Genomics, Region V\u00e4stra G\u00f6taland, Sahlgrenska University Hospital , Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Erlinge","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Clinical Sciences, Lund University , Lund ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2071-5866","authenticated-orcid":false,"given":"Tove","family":"Fall","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Molecular Epidemiology, Uppsala University , Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7294-9667","authenticated-orcid":false,"given":"Ljubica","family":"Matic","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine and Surgery, Karolinska Institute , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"S\u00f6derberg","sequence":"additional","affiliation":[{"name":"Department of Public Health and Clinical Medicine, Ume\u00e5 University , Ume\u00e5 ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl Johan","family":"\u00d6stgren","sequence":"additional","affiliation":[{"name":"Center for Medical Image Science and Visualization (CMIV), Link\u00f6ping University , Link\u00f6ping ,","place":["Sweden"]},{"name":"Department of Health, Medicine and Caring Sciences, Link\u00f6ping University , Link\u00f6ping ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2386-9927","authenticated-orcid":false,"given":"Chris J","family":"Packard","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular and Medical Sciences, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0786-8091","authenticated-orcid":false,"given":"Jan","family":"Bor\u00e9n","sequence":"additional","affiliation":[{"name":"Institute of Medicine, University of Gothenburg , Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"key":"2026070619572479500_ehaf1124-B1","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"2026070619572479500_ehaf1124-B2","doi-asserted-by":"publisher","first-page":"e1082","DOI":"10.1161\/CIR.0000000000000625","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"2026070619572479500_ehaf1124-B3","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ahj.2018.09.011","article-title":"Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study","volume":"206","author":"Pradhan","year":"2018","journal-title":"Am Heart J"},{"key":"2026070619572479500_ehaf1124-B4","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.jacc.2021.01.027","article-title":"Apolipoprotein B and non-HDL cholesterol better reflect residual risk than LDL cholesterol in statin-treated patients","volume":"77","author":"Johannesen","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026070619572479500_ehaf1124-B5","doi-asserted-by":"publisher","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies \u2013 a consensus statement from the European Atherosclerosis Society","volume":"42","author":"Ginsberg","year":"2021","journal-title":"Eur Heart J"},{"key":"2026070619572479500_ehaf1124-B6","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1097\/MED.0000000000000619","article-title":"Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease risk: current status and treatments","volume":"28","author":"Reyes-Soffer","year":"2021","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"2026070619572479500_ehaf1124-B7","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/MED.0000000000000530","article-title":"Triglycerides and residual risk","volume":"27","author":"Vallejo-Vaz","year":"2020","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"2026070619572479500_ehaf1124-B8","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s11892-024-01555-1","article-title":"Impact of remnant cholesterol on cardiovascular risk in diabetes","volume":"24","author":"Elias-Lopez","year":"2024","journal-title":"Curr Diab Rep"},{"key":"2026070619572479500_ehaf1124-B9","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1016\/j.jacc.2024.07.034","article-title":"Quantifying triglyceride-rich lipoprotein atherogenicity, associations with inflammation, and implications for risk assessment using non-HDL cholesterol","volume":"84","author":"Bj\u00f6rnson","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026070619572479500_ehaf1124-B10","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1093\/eurheartj\/ehaf207","article-title":"ApoB-containing lipoproteins: count, type, size, and risk of coronary artery disease","volume":"46","author":"Morze","year":"2025","journal-title":"Eur Heart J"},{"key":"2026070619572479500_ehaf1124-B11","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jacc.2023.10.039","article-title":"Lipoprotein(a) is markedly more atherogenic than LDL: an apolipoprotein B-based genetic analysis","volume":"83","author":"Bj\u00f6rnson","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026070619572479500_ehaf1124-B12","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.jacc.2023.09.836","article-title":"Per-particle cardiovascular risk of lipoprotein(a) vs non-Lp(a) apolipoprotein B-containing lipoproteins","volume":"83","author":"Marston","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026070619572479500_ehaf1124-B13","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1016\/j.jacc.2024.04.008","article-title":"Apob is ready for prime time","volume":"83","author":"Remaley","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026070619572479500_ehaf1124-B14","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1093\/eurheartj\/ehae258","article-title":"Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention","volume":"45","author":"Sniderman","year":"2024","journal-title":"Eur Heart J"},{"key":"2026070619572479500_ehaf1124-B15","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"2026070619572479500_ehaf1124-B16","doi-asserted-by":"publisher","first-page":"100774","DOI":"10.1016\/j.lanepe.2023.100774","article-title":"Non-HDL cholesterol and residual risk of cardiovascular events in patients with ischemic heart disease and well-controlled LDL cholesterol: a cohort study","volume":"36","author":"Hansen","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"2026070619572479500_ehaf1124-B17","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1161\/CIRCULATIONAHA.123.064296","article-title":"Childhood Non-HDL Cholesterol and LDL Cholesterol and Adult Atherosclerotic Cardiovascular Events","volume":"149","author":"Wu","year":"2024","journal-title":"Circulation"},{"key":"2026070619572479500_ehaf1124-B18","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1016\/S0140-6736(19)32519-X","article-title":"Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk Consortium","volume":"394","author":"Brunner","year":"2019","journal-title":"Lancet"},{"key":"2026070619572479500_ehaf1124-B19","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s12944-024-02307-6","article-title":"Lipoprotein(a) and risk-weighted apolipoprotein B: a novel metric for atherogenic risk","volume":"23","author":"Rehman","year":"2024","journal-title":"Lipids Health Dis"},{"key":"2026070619572479500_ehaf1124-B20","doi-asserted-by":"publisher","first-page":"e1001779","DOI":"10.1371\/journal.pmed.1001779","article-title":"UK Biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age","volume":"12","author":"Sudlow","year":"2015","journal-title":"PLoS Med"},{"key":"2026070619572479500_ehaf1124-B21","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/joim.12384","article-title":"The Swedish CArdioPulmonary BioImage Study: objectives and design","volume":"278","author":"Bergstr\u00f6m","year":"2015","journal-title":"J Intern Med"},{"key":"2026070619572479500_ehaf1124-B22","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1161\/CIRCULATIONAHA.119.041149","article-title":"Comparison of conventional lipoprotein tests and apolipoproteins in the prediction of cardiovascular disease","volume":"140","author":"Welsh","year":"2019","journal-title":"Circulation"},{"key":"2026070619572479500_ehaf1124-B23","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41569-022-00676-y","article-title":"Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia","volume":"19","author":"Bor\u00e9n","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"2026070619572479500_ehaf1124-B24","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jacl.2024.09.009","article-title":"Variance in the composition and number of VLDL and LDL particles with increasing triglyceride or increasing ApoB concentrations","volume":"19","author":"Cole","year":"2025","journal-title":"J Clin Lipidol"},{"key":"2026070619572479500_ehaf1124-B25","doi-asserted-by":"publisher","first-page":"4186","DOI":"10.1093\/eurheartj\/ehad337","article-title":"Triglyceride-rich lipoprotein remnants, low-density lipoproteins, and risk of coronary heart disease: a UK Biobank study","volume":"44","author":"Bj\u00f6rnson","year":"2023","journal-title":"Eur Heart J"},{"key":"2026070619572479500_ehaf1124-B26","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"290","author":"Authors\/Task Force Members","year":"2019","journal-title":"Atherosclerosis"},{"key":"2026070619572479500_ehaf1124-B27","doi-asserted-by":"publisher","first-page":"120479","DOI":"10.1016\/j.atherosclerosis.2025.120479","article-title":"2025 Focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"409","author":"Mach","year":"2025","journal-title":"Atherosclerosis"},{"key":"2026070619572479500_ehaf1124-B28","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1001\/jamacardio.2021.5083","article-title":"Association of apolipoprotein B-containing lipoproteins and risk of myocardial infarction in individuals with and without atherosclerosis: distinguishing between particle concentration, type, and content","volume":"7","author":"Marston","year":"2022","journal-title":"JAMA Cardiol"},{"key":"2026070619572479500_ehaf1124-B29","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1001\/jama.2018.20045","article-title":"Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease","volume":"321","author":"Ference","year":"2019","journal-title":"JAMA"},{"key":"2026070619572479500_ehaf1124-B30","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1093\/eurjpc\/zwac219","article-title":"Cholesterol not particle concentration mediates the atherogenic risk conferred by apolipoprotein B particles: a Mendelian randomization analysis","volume":"29","author":"Helgadottir","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"2026070619572479500_ehaf1124-B31","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41569-024-01111-0","article-title":"Apolipoprotein B-containing lipoproteins in atherogenesis","volume":"22","author":"Bor\u00e9n","year":"2025","journal-title":"Nat Rev Cardiol"},{"key":"2026070619572479500_ehaf1124-B32","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1093\/clinchem\/hvae046","article-title":"Worldwide increasing use of nonfasting rather than fasting lipid profiles","volume":"70","author":"Langsted","year":"2024","journal-title":"Clin Chem"},{"key":"2026070619572479500_ehaf1124-B33","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1001\/jama.298.3.309","article-title":"Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women","volume":"298","author":"Bansal","year":"2007","journal-title":"JAMA"},{"key":"2026070619572479500_ehaf1124-B34","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1161\/CIRCULATIONAHA.108.777334","article-title":"Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events","volume":"118","author":"Mora","year":"2008","journal-title":"Circulation"},{"key":"2026070619572479500_ehaf1124-B35","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.atherosclerosis.2019.12.005","article-title":"Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM","volume":"294","author":"Nordestgaard","year":"2020","journal-title":"Atherosclerosis"},{"key":"2026070619572479500_ehaf1124-B36","doi-asserted-by":"publisher","first-page":"e025858","DOI":"10.1161\/JAHA.122.025858","article-title":"Physiological bases for the superiority of apolipoprotein B over low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol as a marker of cardiovascular risk","volume":"11","author":"Glavinovic","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2026070619572479500_ehaf1124-B37","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1001\/jamacardio.2019.3780","article-title":"Apolipoprotein B particles and cardiovascular disease: a narrative review","volume":"4","author":"Sniderman","year":"2019","journal-title":"JAMA Cardiol"},{"key":"2026070619572479500_ehaf1124-B38","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1093\/eurheartj\/ehaf204","article-title":"ApoB and Lp(a): core measures to assess cardiovascular risk","volume":"46","author":"Sniderman","year":"2025","journal-title":"Eur Heart J"},{"key":"2026070619572479500_ehaf1124-B39","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.jacl.2025.05.024","article-title":"ApoB, LDL-C, and non-HDL-C as markers of cardiovascular risk","volume":"19","author":"Sehayek","year":"2025","journal-title":"J Clin Lipidol"},{"key":"2026070619572479500_ehaf1124-B40","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1093\/eurheartj\/ehaf214","article-title":"Great debate: plasma triglycerides are an important causal factor and therapeutic target for atherosclerotic cardiovascular disease","volume":"46","author":"Bor\u00e9n","year":"2025","journal-title":"Eur Heart J"},{"key":"2026070619572479500_ehaf1124-B41","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1161\/ATVBAHA.124.321165","article-title":"Discordance analysis of VLDL-C and ApoB in UK Biobank and Framingham study: a prospective observational study","volume":"44","author":"Bilgic","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026070619572479500_ehaf1124-B42","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/47\/26\/3415\/66531065\/ehaf1124.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/47\/26\/3415\/66531065\/ehaf1124.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T23:57:34Z","timestamp":1783382254000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/47\/26\/3415\/8436832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":42,"journal-issue":{"issue":"26","published-online":{"date-parts":[[2026,1,22]]},"published-print":{"date-parts":[[2026,7,7]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehaf1124","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7,7]]},"published":{"date-parts":[[2026,1,22]]}}}